Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$159.61 USD

159.61
6,904,502

-3.32 (-2.04%)

Updated May 22, 2024 04:00 PM ET

Pre-Market: $159.61 0.00 (0.00%) 9:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.

    AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

    by Zacks Equity Research

    AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.

      AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA

      by Zacks Equity Research

      AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.

        AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

        by Zacks Equity Research

        AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

          Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

          by Zacks Equity Research

          Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

            Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

            by Zacks Equity Research

            Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).

              Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

              by Zacks Equity Research

              Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate

                Infinity (INFI) Reports Narrower-than-Expected Loss in Q4

                by Zacks Equity Research

                Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.

                  Novartis (NVS) Reports Positive Data on Biosimilar Humira

                  by Zacks Equity Research

                  Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.

                    Inovio (INO): What's in the Cards this Earnings Season?

                    by Zacks Equity Research

                    Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.

                      BioDelivery (BDSI): What's in Store this Earnings Season?

                      by Zacks Equity Research

                      BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.

                        J&J Presents Positive Phase III Data on Psoriasis Candidate

                        by Zacks Equity Research

                        Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.

                          Arpita Dutt headshot

                          Pricing to Remain Pharma Headline Risk in 2017

                          by Arpita Dutt

                          Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.

                            Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

                            by Zacks Equity Research

                            Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

                              Gilead (GILD) Announces Data on Combination Therapy for HIV

                              by Zacks Equity Research

                              Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

                                Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

                                by Zacks Equity Research

                                Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

                                  The Zacks Analyst Blog Highlights: Apple, Visa and AbbVie

                                  by Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: Apple, Visa and AbbVie

                                    Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales

                                    by Zacks Equity Research

                                    Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.

                                      AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada

                                      by Zacks Equity Research

                                      AbbVie Inc. (ABBV) announced that its New Drug Submission (NDS) for an investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) received priority review in Canada for treatment of HCV.

                                        Arpita Dutt headshot

                                        Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

                                        by Arpita Dutt

                                        2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

                                          Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

                                          by Zacks Equity Research

                                          Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

                                            Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

                                            by Zacks Equity Research

                                            Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

                                              AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag

                                              by Zacks Equity Research

                                              AbbVie (ABBV) reported earnings of $1.20 in the fourth-quarter of 2016, with revenues coming in at $6.80 billion.

                                                AbbVie (ABBV) Reports In-Line Q4 Earnings, Revenues Miss

                                                by Zacks Equity Research

                                                AbbVie (ABBV) reported earnings of $1.20 in the fourth-quarter of 2016, with revenues coming in at $6.80 billion.

                                                  Tracey Ryniec headshot

                                                  Friday's Best Earnings Charts

                                                  by Tracey Ryniec

                                                  It's not easy to beat the estimate nearly every quarter.